The therapeutic myth

  • F. Neil Johnson

Abstract

In 1967, a young doctor by the name of Barry Blackwell completed his training in both psychiatry and pharmacology at the Maudsley Hospital in London. He was offered, and accepted, a place as a Research Fellow at the Maudsley, and worked for the next year with Professor Michael Shepherd who was then Professor of Epidemiological Psychiatry.1 At that time, the claims for lithium prophylaxis were beginning to be loudly heard, and Blackwell’s interest in the topic was immediately aroused. He and Shepherd examined the data that were available and came to the conclusion that the claims for prophylactic efficacy were simply not supported by the evidence. They presented their argument in an article entitled ‘Prophylactic lithium: another therapeutic myth?’ which was published in the Lancet on 4 May 1968.2

Keywords

Placebo Depression Europe Lithium Aspirin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes and references

  1. 2.
    Blackwell, B. and Shepherd, M. (1968) ‘Prophylactic lithium: another therapeutic myth? An examination of the evidence to date’, Lancet, i, 968–71.CrossRefGoogle Scholar
  2. 3.
    Baastrup, P. C. and Schou, M. (1967) ‘Lithium as a prophylactic agent. Its effect against recurrent depressions and manic-depressive psychosis’, Archives of General Psychiatry, 16, 162–72.CrossRefGoogle Scholar
  3. 4.
    Blackwell and Shepherd, ‘Prophylactic lithium: another therapeutic myth?’, 968 (note 2).CrossRefGoogle Scholar
  4. 5.
    Ibid., 969.Google Scholar
  5. In the original passage a series of footnote references indicated which patients were being referred to, as identified by the code numbers used by Baastrup and Schou in their article ‘Lithium as a prophylactic agent’ (note 3).CrossRefGoogle Scholar
  6. 6.
    Blackwell and Shepherd, ‘Prophylactic lithium: another therapeutic myth?’, 969 (note 2).CrossRefGoogle Scholar
  7. 7.
    Ibid., 970.Google Scholar
  8. 9.
    Baastrup, P. C. and Schou, M. (1968) ‘Prophylactic lithium’, Lancet, i, 1419–22.CrossRefGoogle Scholar
  9. 10.
    Ibid., 1420.Google Scholar
  10. 11.
  11. 12.
  12. 13.
    Hullin, R. P., McDonald, R., Anderson, W. McC. and Geraghty, S. M. J. (1968) ‘Prophylactic lithium’, Lancet, i, 1155–56.CrossRefGoogle Scholar
  13. 14.
    Laurell, B. and Ottosson, J. O. (1968) ‘Prophylactic lithium?’, Lancet, ii, 1245–46.CrossRefGoogle Scholar
  14. 15.
  15. 16.
  16. 17.
    Fieve, R. R. and Platman, S. R. (1968) ‘Prophylactic lithium?’, Lancet, i, 830.CrossRefGoogle Scholar
  17. 18.
  18. 19.
  19. 20.
    Lader, M. H. (1968) ‘Prophylactic lithium’, Lancet, ii, 103.CrossRefGoogle Scholar
  20. 21.
  21. 22.
  22. 24.
    Baastrup, P. C. and Schou, M. (1968) ‘Prophylactic lithium?’ Lancet, ii, 349–50.CrossRefGoogle Scholar
  23. 25.
    Sargant, W. (1968) ‘Prophylactic lithium?’ Lancet, ii, 216.CrossRefGoogle Scholar
  24. 26.
    Kline, N. S. (1968) ‘Lithium comes into its own’, American Journal of Psychiatry, 125, 558–60.CrossRefGoogle Scholar
  25. 27.
  26. 28.
  27. 29.
  28. 30.
    Blackwell, B. (1969) ‘Need for careful evaluation of lithium’, American Journal of Psychiatry, 125, 1131.CrossRefGoogle Scholar
  29. 31.
    Kline, N. S. (1969) ‘Dr Kline replies’, American Journal of Psychiatry, 125, 1311.CrossRefGoogle Scholar
  30. 32.
    Blackwell, B. (1969) ‘Lithium: prophylactic or panacea?’, Medical Counterpoint, November, 52–59.Google Scholar
  31. 33.
    Ibid., 52.Google Scholar
  32. 34.
    Ibid., 54.Google Scholar
  33. 35.
    Ibid., 56.Google Scholar
  34. 36.
    Ibid., 52.Google Scholar
  35. 37.
    Ibid., 59.Google Scholar
  36. 38.
    Shepherd, M. (1970–71) ‘A prophylactic myth’, International Journal of Pychiatry, 9, 423–25.Google Scholar
  37. 39.
    Ibid., 425.Google Scholar
  38. 40.
    Shull, W. K. and Sapira, J. D. (1970) ‘Critique of studies of lithium salts in the treatment of mania’, American Journal of Psychiatry, 127, 218–22.CrossRefGoogle Scholar
  39. 45.
    Schou, M. (1974) ‘Ethical problems of therapeutic and prophylactic trials in manic-depressive disorder’. In, Bohaček, N. and Mihovilovič, M. (eds) Psihofarmakologija 3: Proceedings of the 3rd Yugoslav Psychopharmocological Symposium, Opatija, 1973 (Zagreb: Medicinska Naklada) 323–28. Quotation from 325–26.Google Scholar
  40. 46.
    Ibid., 326.Google Scholar
  41. 47.
    Baastrup, P. C., Poulsen, J. C., Schou, M., Thomsen, K. and Amdisen, A. (1970) ‘Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent-depressive disorders,’ Lancet, ii, 326–30.CrossRefGoogle Scholar
  42. 49.
    Blackwell, B. (1970) ‘Lithium’, Lancet, ii, 875.CrossRefGoogle Scholar
  43. 50.
    Schou, M. (1970) ‘Lithium’, Lancet, ii, 875–76.Google Scholar
  44. 51.
    Mantel, N. (1971) ‘Prophylactic lithium’, Lancet, i, 758;CrossRefGoogle Scholar
  45. Schou, M. and Thomsen, K. (1971) ‘Prophylactic lithium’, Lancet, i, 1066;CrossRefGoogle Scholar
  46. Armitage, P. (1971) ‘Prophylactic lithium’, Lancet, i, 1066;Google Scholar
  47. Mantel, N. (1971) ‘Sequential methods in clinical trials’, Lancet, i, 1182–83.Google Scholar
  48. 52.
    Blackwell, B. (1972) ‘Prophylactic lithium: science or science fiction?’, American Heart Journal, 83, 139–41.CrossRefGoogle Scholar
  49. 53.
  50. 55.
    Shepherd, M. (1974) ‘Discussion’. In, Bohaček and Mihovilovič, M. (eds) Psihofarmakologija 3: Proceedings of the 3rd Yugoslav Psychopharmacological Symposium, Opatija, 1973 (Zagreb: Medicinska Noklada) 329–30. Quotation from 329.Google Scholar
  51. 56.
    Ibid., 330.Google Scholar
  52. 57.
    Baastrup and Schou, ‘Prophylactic lithium’ (note 9).CrossRefGoogle Scholar
  53. 58.
    Blackwell and Shepherd, ‘Prophylactic lithium: another therapeutic myth?’ (note 2).CrossRefGoogle Scholar
  54. 59.
    Schou, M. (1974) ‘Discussion’. In, Bohaček, N. and Mihovilovič, M. (eds) Psihofarmakologija 3: Proceedings of the 3rd Yugoslav Psychopharmacological Symposium, Opatija, 1973 (Zagreb: Medicinska Noklada) 330–32. Quotation from 331.Google Scholar
  55. 62.
    Schou, M., Thomsen, K. and Baastrup, P. C. (1970) ‘Studies on the course of recurrent endogenous affective disorders’, International Pharrnacopsychiatry, 5, 100–06.Google Scholar
  56. 64.
    The error appears in line 11 of the left-hand column on page 328 of Baastrup et al., ‘Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent-depressive disorders’ (note 47).CrossRefGoogle Scholar
  57. 71.
    Schou, M. and Strömgren, E. (eds) (1979) Origin, Prevention and Treatment of Affective Disorders (London: Academic Press).Google Scholar
  58. 74.
    Medical Research Council Drug Trials Subcommittee (1981) ‘Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a controlled trial’, Psychological Medicine, 11, 409–16.CrossRefGoogle Scholar
  59. 75.
    The principles of prophylactic trials which had been so well worked out by Jules Angst and Paul Grof were subsequently presented in a form applicable to trials of all substances which have a suspected prophylactic effect: Grof, P., Schou, M., Angst, J., Baastrup, P. C. and Weis, P. (1970) ‘Methodological problems of prophylactic trials in recurrent affective disorders’, British Journal of Psychiatry, 116, 599–619.CrossRefGoogle Scholar
  60. 76.
    Schou, M. (1973) ‘Prophylactic lithium maintenance treatment in recurrent endogenous affective disorders’. In, Gershon, S. and Shopsin, B. (eds) Lithium: Its Role in Psychiatric Research and Treatment (New York: Plenum) 269–94. Quotation from 286–87.CrossRefGoogle Scholar

Copyright information

© F. Neil Johnson 1984

Authors and Affiliations

  • F. Neil Johnson
    • 1
  1. 1.Department of PsychologyUniversity of LancasterUK

Personalised recommendations